Equities Analysts Set Expectations for COAG FY2027 Earnings

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) – Equities research analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for Hemab Therapeutics in a note issued to investors on Monday, July 13th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($2.81) for the year, down from their previous forecast of ($2.69). HC Wainwright has a “Buy” rating and a $52.00 price target on the stock. HC Wainwright also issued estimates for Hemab Therapeutics’ FY2028 earnings at ($3.63) EPS, FY2029 earnings at ($3.89) EPS and FY2030 earnings at ($2.44) EPS.

Hemab Therapeutics (NASDAQ:COAG) last issued its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Several other research firms also recently commented on COAG. Evercore initiated coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective for the company. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price objective on the stock. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Finally, Wedbush reissued an “outperform” rating and set a $55.00 target price (up from $42.00) on shares of Hemab Therapeutics in a research report on Monday. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Hemab Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $48.00.

Hemab Therapeutics Stock Up 9.6%

COAG stock opened at $43.31 on Wednesday. The company has a market cap of $2.02 billion and a PE ratio of -1.81. The stock’s 50-day moving average is $28.99. Hemab Therapeutics has a 1 year low of $23.00 and a 1 year high of $43.92.

Insider Buying and Selling at Hemab Therapeutics

In other news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the acquisition, the director owned 6,149,096 shares in the company, valued at $110,683,728. This trade represents a 77.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have bought 2,970,541 shares of company stock worth $55,459,603 over the last 90 days.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.